Clinical and Translational Oncology

, Volume 16, Issue 3, pp 257–265 | Cite as

The clinical significance of memory T cells and its subsets in gastric cancer

Research Article

Abstract

Background

Long life of memory T cell (Tm) determines its crucial role in the carcinogenesis and carcinogenic progression which usually take long time. The Tm compartment contains two populations, central memory T cells (Tcm) and effector memory T cells (Tem), based on their phenotypic markers, functional attributes, and migratory properties.

Methods

We investigated the subsets of the Tm in peripheral blood and tumor microenvironments in patients with gastric cancer by flow cytometry, and aimed to explore the correlation between the Tm and clinicopathologic features of gastric cancer.

Results

The percentages of CD4+/CD8+ Tm and CD4+/CD8+ Tcm in peripheral blood from gastric cancer patients were statistically lower, whereas the percentages of CD4+/CD8+ Tem were significantly higher than healthy controls. The proportion of CD4+/CD8+ Tcm increased after tumor resection, while the percentage of the CD4+/CD8+ Tem decreased significantly. Significant associations were detected between the peripheral CD4+/CD8+ Tm and clinical stage, as well as the CD8+ Tcm and clinical stage and nodal involvement. Tumor infiltrating CD8+ Tm expressed both central and effector memory phenotypes, whereas CD4+ Tm displayed predominantly an effector memory phenotype. Higher percentages of tumor infiltrating CD4+/CD8+ Tm were significantly associated with the early disease stage.

Conclusions

Tm and its subsets were good immune indicators for the disease stage of gastric cancer. The proportion of Tm subsets may reflect the immune suppressive and immune response to the tumor associated antigen.

Keywords

Gastric cancer Memory T cell Immune CD45RO Surgery 

References

  1. 1.
    Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754):708–12.PubMedCrossRefGoogle Scholar
  2. 2.
    Manjunath N, Shankar P, Wan J, Weninger W, Crowley MA, Hieshima K, et al. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J Clin Invest. 2001;108(6):871–8.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003;4(3):225–34.PubMedCrossRefGoogle Scholar
  4. 4.
    Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA. 2005;102(27):9571–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006;211:214–24.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Lalvani A, Brookes R, Hambleton S, Britton WJ, Hill AV, McMichael AJ. Rapid effector function in CD8+ memory T cells. J Exp Med. 1997;186(6):859–65.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Novy P, Quigley M, Huang X, Yang Y. CD4 T cells are required for CD8 T cell survival during both primary and memory recall responses. J Immunol. 2007;179(12):8243–51.PubMedGoogle Scholar
  8. 8.
    Hwang ML, Lukens JR, Bullock TN. Cognate memory CD4+ T cells generated with dendritic cell priming influence the expansion, trafficking, and differentiation of secondary CD8+ T cells and enhance tumor control. J Immunol. 2007;179(9):5829–38.PubMedGoogle Scholar
  9. 9.
    Merkenschlager M, Terry L, Edwards R, Beverley PC. Limiting dilution analysis of proliferative responses in human lymphocyte populations defined by the monoclonal antibody UCHL1: implications for differential CD45 expression in T cell memory formation. Eur J Immunol. 1988;18(11):1653–61.PubMedCrossRefGoogle Scholar
  10. 10.
    Hotta K, Sho M, Fujimoto K, Shimada K, Yamato I, Anai S, et al. Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma. Br J Cancer. 2011;105(8):1191–6.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Xiang R, Lode HN, Gillies SD, Reisfeld RA. T cell memory against colon carcinoma is long-lived in the absence of antigen. J Immunol. 1999;163(7):3676–83.PubMedGoogle Scholar
  12. 12.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRefGoogle Scholar
  13. 13.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.PubMedCrossRefGoogle Scholar
  14. 14.
    Belov L, Zhou J, Christopherson RI. Cell surface markers in colorectal cancer prognosis. Int J Mol Sci. 2010;12(1):78–113.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29(8):1093–102.PubMedCrossRefGoogle Scholar
  16. 16.
    Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2010;138(4):1429–40.PubMedCrossRefGoogle Scholar
  17. 17.
    Bindea G, Mlecnik B, Fridman WH, Galon J. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol. 2011;33(4):335–40.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Hara M, Matsuzaki Y, Shimizu T, Tomita M, Ayabe T, Enomoto Y, et al. Preoperative peripheral naive/memory ratio and prognosis of nonsmall-cell lung cancer patients. Ann Thorac Cardiovasc Surg. 2007;13(6):384–90.PubMedGoogle Scholar
  19. 19.
    Kuss I, Schaefer C, Godfrey TE, Ferris RL, Harris JM, Gooding W, et al. Recent thymic emigrants and subsets of naive and memory T cells in the circulation of patients with head and neck cancer. Clin Immunol. 2005;116(1):27–36.PubMedCrossRefGoogle Scholar
  20. 20.
    Sallusto F, Lanzavecchia A. Exploring pathways for memory T cell generation. J Clin Invest. 2001;108(6):805–6.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Barbieri C, Fujisawa MM, Yasuda CL, Metze IL, Oliveira EC, Santos LM, et al. Effect of surgical treatment on the cellular immune response of gastric cancer patients. Braz J Med Biol Res. 2003;36(3):339–45.PubMedCrossRefGoogle Scholar
  22. 22.
    Tanel A, Fonseca SG, Yassine-Diab B, Bordi R, Zeidan J, Shi Y, et al. Cellular and molecular mechanisms of memory T-cell survival. Expert Rev Vaccin. 2009;8(3):299–312.CrossRefGoogle Scholar
  23. 23.
    Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. 2002;2(4):251–62.PubMedCrossRefGoogle Scholar
  24. 24.
    Rauser S, Langer R, Tschernitz S, Gais P, Jutting U, Feith M, et al. High number of CD45RO+ tumor infiltrating lymphocytes is an independent prognostic factor in non-metastasized (stage I–IIA) esophageal adenocarcinoma. BMC Cancer. 2010;10:608.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353(25):2654–66.PubMedCrossRefGoogle Scholar
  26. 26.
    Broussard EK, Disis ML. TNM staging in colorectal cancer: T is for T cell and M is for memory. J Clin Oncol. 2011;29(6):601–3.PubMedCrossRefGoogle Scholar
  27. 27.
    Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010;222(4):350–66.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Lee HE, Chae SW, Lee YJ, Kim MA, Lee HS, Lee BL, et al. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer. 2008;99(10):1704–11.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2013

Authors and Affiliations

  1. 1.Department of Gastric Cancer Surgery, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and HospitalTianjinChina
  2. 2.Cancer Prevention Center, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and HospitalTianjinChina
  3. 3.Department of Immunology, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and HospitalTianjinChina

Personalised recommendations